Greenwich Financial Statements From 2010 to 2025

GLSI Stock  USD 12.87  0.30  2.39%   
Greenwich Lifesciences financial statements provide useful quarterly and yearly information to potential Greenwich Lifesciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Greenwich Lifesciences financial statements helps investors assess Greenwich Lifesciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Greenwich Lifesciences' valuation are summarized below:
Market Capitalization
169.2 M
Earnings Share
(0.83)
We have found one hundred twelve available fundamental trends for Greenwich Lifesciences, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Greenwich Lifesciences regular fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The Greenwich Lifesciences' current Market Cap is estimated to increase to about 305.2 M. The Greenwich Lifesciences' current Enterprise Value is estimated to increase to about 240.3 M
Check Greenwich Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Greenwich Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 K, Interest Expense of 259.6 K or Selling General Administrative of 1.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 19.06. Greenwich financial statements analysis is a perfect complement when working with Greenwich Lifesciences Valuation or Volatility modules.
  
Check out the analysis of Greenwich Lifesciences Correlation against competitors.
For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

Greenwich Lifesciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14 MM6.2 M
Slightly volatile
Other Current Liabilities311.1 K233 K405.4 K
Slightly volatile
Total Current Liabilities251.7 K265 K652.4 K
Slightly volatile
Other Liabilities7.6 M8.6 M9.3 M
Slightly volatile
Accounts Payable30.3 K31.9 K252.7 K
Slightly volatile
Cash14 MM6.2 M
Slightly volatile
Non Current Assets Total4.6 K4.9 K17.7 K
Slightly volatile
Cash And Short Term Investments14 MM6.2 M
Slightly volatile
Common Stock Total Equity15.9 K15.1 KK
Slightly volatile
Common Stock Shares Outstanding13.8 M14.8 M12.5 M
Slightly volatile
Liabilities And Stockholders Equity14 MM6.2 M
Slightly volatile
Other Stockholder Equity49.2 M65.6 M30.8 M
Slightly volatile
Total Liabilities251.7 K265 KM
Slightly volatile
Total Current Assets14 MM6.2 M
Slightly volatile
Capital Stock11.8 K14.8 K6.8 K
Slightly volatile
Intangible Assets4.6 K4.9 K17.7 K
Slightly volatile
Common Stock11 K14.8 K5.5 K
Slightly volatile
Short and Long Term Debt Total364248504
Slightly volatile
Short Term Debt364248504
Slightly volatile
Capital Surpluse64.4 M69.5 M58.7 M
Slightly volatile

Greenwich Lifesciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And AmortizationK4.2 K3.7 K
Slightly volatile
Selling General Administrative1.2 M1.9 M791.2 K
Slightly volatile
Other Operating Expenses11.3 M10.7 MM
Slightly volatile
Research Development9.3 M8.9 M3.2 M
Slightly volatile
Total Operating Expenses11.3 M10.7 MM
Slightly volatile
Reconciled DepreciationK4.2 K3.7 K
Slightly volatile
Cost Of RevenueK4.2 K3.7 K
Slightly volatile
Total Other Income Expense Net526.5 K501.5 K106.7 K
Slightly volatile
Net Interest Income544.5 K518.6 K110.3 K
Slightly volatile
Interest Income544.5 K518.6 K110.3 K
Slightly volatile
Non Operating Income Net Other33 K31.5 K9.7 K
Slightly volatile
Selling And Marketing Expenses2.9 K3.3 K3.5 K
Slightly volatile

Greenwich Lifesciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow12.7 M15.5 M6.1 M
Slightly volatile
DepreciationK4.2 K3.7 K
Slightly volatile
Change To Operating Activities121 K127.4 KM
Slightly volatile
End Period Cash Flow14 MM6.2 M
Slightly volatile
Change To Netincome475.3 K759.7 K365.3 K
Slightly volatile
Stock Based Compensation2.9 M2.7 M813.5 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables206.9 K147.4 K224.2 K
Slightly volatile
Payables Turnover0.09620.09160.0333
Slightly volatile
Cash Per Share0.680.490.4452
Slightly volatile
Days Payables Outstanding3.9 K4.1 K19.2 K
Very volatile
Income Quality0.380.660.3054
Slightly volatile
Intangibles To Total Assets8.0E-49.0E-40.1682
Slightly volatile
Current Ratio19.7821.3713.3927
Slightly volatile
Graham Number1.972.562.0083
Slightly volatile
Interest Debt Per Share0.00.00.0198
Slightly volatile
Debt To Assets0.00.02.1788
Slightly volatile
Days Of Payables Outstanding3.9 K4.1 K19.2 K
Very volatile
Ebt Per Ebit1.081.11.006
Slightly volatile
Quick Ratio19.7821.3713.3927
Slightly volatile
Net Income Per E B T1.091.121.009
Slightly volatile
Cash Ratio19.7821.3713.3927
Slightly volatile
Debt Ratio0.00.02.1788
Slightly volatile

Greenwich Lifesciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap305.2 M155.4 M387.7 M
Slightly volatile
Enterprise Value240.3 M147.4 M125.5 M
Slightly volatile

Greenwich Fundamental Market Drivers

Cash And Short Term InvestmentsM

Greenwich Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
27th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Greenwich Lifesciences Financial Statements

Investors use fundamental indicators, such as Greenwich Lifesciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Greenwich Lifesciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue(316.42)(332.24)
Cost Of Revenue4.2 KK

Currently Active Assets on Macroaxis

When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:
Check out the analysis of Greenwich Lifesciences Correlation against competitors.
For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.83)
Return On Assets
(0.72)
Return On Equity
(1.24)
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.